Male breast cancer: a gender issue

被引:32
作者
Nahleh, Zeina [1 ]
Girnius, Saulius [1 ]
机构
[1] Univ Cincinnati, Coll Med, Div Hematon Oncol,Barrett Canc Ctr, Breast Oncol Program, Cincinnati, OH 45267 USA
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 08期
关键词
breast cancer; differences; gender; hormonal; male breast cancer;
D O I
10.1038/ncponc0564
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of male breast cancer (MBC) is rising; however, mortality due to MBC has not changed, unlike female breast cancer. This lack of change is mostly attributable to a lack of major progress in the understanding and treatment of the disease. The treatment of MBC has been extrapolated from the knowledge of female breast cancer, despite the multiple differences in the pathogenesis, biology and genetics of these two disease entities, especially the differences with regard to the role of male hormones as well as estrogens in MBC compared with female disease. Although major advances in hormonal manipulation for the treatment of breast cancer are being developed, an improved understanding of the potential differences between male and female breast cancer is essential, as this would provide new opportunities for therapeutic intervention and probable improved outcome for MBC. this review aims at highlighting the major differences between male and female breast cancer with an emphasis on hormonal therapy, and discuss some of the recent advances in MBC.
引用
收藏
页码:428 / 437
页数:10
相关论文
共 122 条
  • [1] Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy
    Albo, D
    Ames, FC
    Hunt, KK
    Ross, MI
    Singletary, SE
    Kuerer, HM
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (01) : 9 - 14
  • [2] American Cancer Society, 2005, CANC FACTS FIG 2005
  • [3] ANDERSEN JA, 1982, ACTA PATH MICRO IM A, V90, P191
  • [4] Is male breast cancer similar or different than female breast cancer?
    Anderson, WF
    Althuis, MD
    Brinton, LA
    Devesa, SS
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (01) : 77 - 86
  • [5] ANELLI A, 1995, CANCER, V75, P2233, DOI 10.1002/1097-0142(19950501)75:9<2233::AID-CNCR2820750907>3.0.CO
  • [6] 2-S
  • [7] [Anonymous], 2001, Endocrinology
  • [8] ADJUVANT CHEMOTHERAPY IN MALES WITH CANCER OF THE BREAST
    BAGLEY, CS
    WESLEY, MN
    YOUNG, RC
    LIPPMAN, ME
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (01): : 55 - 60
  • [9] Baum M, 2002, LANCET, V359, P2131
  • [10] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
    Bonneterre, J
    Thürlimann, B
    Robertson, JFR
    Krzakowski, M
    Mauriac, L
    Koralewski, P
    Vergote, I
    Webster, A
    Steinberg, M
    von Euler, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757